Non Melanoma Skin cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

The cancer type that is most common in the US is skin cancer. The two primary types of skin cancer are melanoma and nonmelanoma skin cancer (NMSC). It is difficult to determine the precise incidence of skin cancer due to poor diagnostic standards and underreporting. There are currently 132,000 new cases of melanoma each year, and 2 to 3 million new cases of non-melanoma skin cancer. Non-melanoma skin cancer (NMSC) is the most common type of cancer in people, with a steadily increasing incidence. Treatment options for skin cancers other than melanoma include basal cell carcinoma, squamous cell carcinoma of the skin, and actinic keratosis. Topical therapies may be utilized to treat superficial basal cell carcinomas and squareamous cell carcinomas, depending on the physician's preference.

Description

The most common cancer in the US is skin cancer. Skin cancer can fall into one of two main categories: melanoma or nonmelanoma skin cancer (NMSC). It is difficult to determine the precise incidence of skin cancer due to subpar diagnostic standards and underreporting. NMSC and melanoma incidence, however, have risen over the past few decades, according to various epidemiologic studies. The detection and management of these neoplasms pose a significant health risk in terms of patient well-being and healthcare costs. Skin cancers are frequently found on the head and neck, and both diagnosis and treatment can be extremely dangerous. Treatment options include surgical excision, radiation, chemotherapy, immunotherapy, and cryotherapy. Sun protection measures, such as sunscreen, are essential to preventing skin cancer.

Non-Melanoma Skin cancer (Epidemiology)

Currently, 132,000 cases of melanoma and 2 to 3 million cases of non-melanoma skin cancer are reported annually throughout the world. Non-melanoma skin cancer (NMSC) is the most common type of cancer in people, with a steadily increasing incidence. The term "NMSC" refers to all skin-related malignant neoplasms other than melanoma. Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), the two primary types of NMSC, account for approximately 99% of all NMSCs. Additional NMSCs include sebaceous carcinoma, apocrine adenocarcinoma, Merkel cell carcinoma, and other rare tumors. BCC predominates, and the ratio of BCC to SCC varies depending on the population, ethnic group, and sex. Despite the fact that NMSC are 18-20 times more common than cutaneous melanoma, there is few epidemiological data for those tumor types. Only a few studies have examined the distinct incidence of BCCs and SCCs due to the lack of differentiation between different types of NMSC in national cancer registry data in the majority of European countries. Any tumor diagnosis based on histopathology and site is coded using the International Classification of Diseases, 11th Revision (ICD-11). Due to cutaneous melanoma's ICD code of C43, the information for this diagnosis is precise. Because a non-homogeneous NMSC group only receives one code (C44) to cover all NMSCs, separate data on BCCs, SCCs, and other skin cancers are not available, making it difficult to count and accurately assess NMSC diagnoses. Age-specific incidence rates and age-adjusted incidence rates (AARs) of skin cancer for all ages (0-75 years) were collected from India and the rest of the world, respectively, based on data from the National Cancer Registry Program and GLOBOCAN 2018. For skin melanoma, the North of India had the highest AAR per 100,000 for both men and women, at 1.62 and 1.21, respectively. Incidences of nonmelanoma of the skin or other skin cancers were highest in the East (6.2) and Northeast (3.49) for men and women, respectively. Both the male (75.6) and female (43.6) sexes had the highest incidence of nonmelanoma in the northeast. Men's skin melanoma rates were highest in the Western Pacific region (36.9) and women's rates were highest in the European region (31.7), according to AAR. Men were more likely to develop nonmelanoma of the skin or other skin cancers in the Western Pacific, where there were 225.4 cases compared to 68.6 cases of women.

Non-Melanoma Skin Cancer-Current Market Size & Forecast Trends

The market for non-melanoma skin cancer (NMSC) is expected to grow from about USD 563.2 million in 2023 to approximately USD 850.1 million by 2032, with a compound annual growth rate (CAGR) of around 4.68%. This growth is driven by the increasing incidence of NMSC, greater awareness of skin cancer, and advancements in treatment options such as surgical procedures and topical therapies. The overall NMSC treatment market is projected to expand significantly as public health initiatives promote prevention and early detection, positioning the market for substantial growth through 2035.

Treatment options exist for skin cancers other than melanoma, such as actinic keratosis, basal cell carcinoma, and squamous cell carcinoma of the skin. Topical therapies may be used to treat superficial basal cell carcinomas and squareamous cell carcinomas, depending on the physician's preference. The standard procedure, however, is to surgically remove these lesions using abrasive methods like electrodesiccation and curettage. Mohs micrographic surgery is a specialized surgical procedure that is typically recommended for skin cancers that are more than 2 cm in diameter and those that are discovered on sensitive body parts (such as the head, neck, hands, feet, and genitalia). Some aggressive and recurrent basal cell carcinoma patients who are poor surgical candidates are treated with radiation therapy or systemic drugs (e. g. treatment of basal cell carcinoma with vismodegib).

Report Highlights

Non-Melanoma Skin cancer- Current Market Trends

Non-Melanoma Skin cancer- Current & Forecasted Cases across the G8 Countries

Non-Melanoma Skin cancer- Market Opportunities and Sales Potential for Agents

Non-Melanoma Skin cancer- Patient-based Market Forecast to 2035

Non-Melanoma Skin cancer- Untapped Business Opportunities

Non-Melanoma Skin cancer- Product Positioning Vis-a-vis Competitors' Products

Non-Melanoma Skin cancer- KOLs Insight